Home › Compare › ERTWF vs ABBV
ERTWF yields 36.04% · ABBV yields 3.06%● Live data
📍 ERTWF pulled ahead of the other in Year 1
Combined, ERTWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ERTWF + ABBV for your $10,000?
Eurotech S.p.A. engages in the research and development, production, and marketing of miniaturized computers and high-performance computers featuring high computing capacity in Italy and internationally. The company offers embedded boards and modules, such as COM Express CPU-modules, small form factor boards, single board computers, VME boards, compact peripheral component interconnect boards, PC/104 boards, and development kits. It also provides embedded and edge computers, HMIs and displays, and expansion modules; mobile access routers, data loggers and storage systems, and networking modules; and high performance embedded computing systems, switches, and boards for data access and management. In addition, the company offers intelligent sensors, such as people counters and environmental monitoring systems; multi-service IoT edge gateways, IoT edge framework, and IoT integration platform; wearable devices and handheld computers, as well as G-Station, a supercomputer solution. Further, it provides IoT consulting and solutions and product design and manufacturing services. The company serves industrial and automation, transportation and mobility, energy and utilities, defense and aerospace, and medical and healthcare markets. Eurotech S.p.A. was founded in 1992 and is headquartered in Amaro, Italy.
Full ERTWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.